Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine
A dengue vaccine has been pursued for more than 50 years and, unlike other flaviviral vaccines such as that against yellow fever, progress has been slow. In this review, we describe progress toward the first licensed dengue vaccine Dengvaxia, which does not give complete protection against disease....
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Cold Spring Harbor Laboratory Press
2018
|
| _version_ | 1797088461714358272 |
|---|---|
| author | Screaton, G Mongkolsapaya, J |
| author_facet | Screaton, G Mongkolsapaya, J |
| author_sort | Screaton, G |
| collection | OXFORD |
| description | A dengue vaccine has been pursued for more than 50 years and, unlike other flaviviral vaccines such as that against yellow fever, progress has been slow. In this review, we describe progress toward the first licensed dengue vaccine Dengvaxia, which does not give complete protection against disease. The antibody response to the dengue virion is reviewed, highlighting immunodominant yet poorly neutralizing responses in the context of a highly dynamic structurally flexible dengue virus particle. Finally, we review recent evidence for cross-reactivity between antibody responses to Zika and dengue viruses, which may further complicate the development of broadly protective dengue virus vaccines. |
| first_indexed | 2024-03-07T02:50:26Z |
| format | Journal article |
| id | oxford-uuid:ad820ada-fb98-4e3c-91cf-494253bf1712 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:50:26Z |
| publishDate | 2018 |
| publisher | Cold Spring Harbor Laboratory Press |
| record_format | dspace |
| spelling | oxford-uuid:ad820ada-fb98-4e3c-91cf-494253bf17122022-03-27T03:35:57ZWhich dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccineJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ad820ada-fb98-4e3c-91cf-494253bf1712EnglishSymplectic Elements at OxfordCold Spring Harbor Laboratory Press2018Screaton, GMongkolsapaya, JA dengue vaccine has been pursued for more than 50 years and, unlike other flaviviral vaccines such as that against yellow fever, progress has been slow. In this review, we describe progress toward the first licensed dengue vaccine Dengvaxia, which does not give complete protection against disease. The antibody response to the dengue virion is reviewed, highlighting immunodominant yet poorly neutralizing responses in the context of a highly dynamic structurally flexible dengue virus particle. Finally, we review recent evidence for cross-reactivity between antibody responses to Zika and dengue viruses, which may further complicate the development of broadly protective dengue virus vaccines. |
| spellingShingle | Screaton, G Mongkolsapaya, J Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine |
| title | Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination?
The challenges of a dengue vaccine |
| title_full | Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination?
The challenges of a dengue vaccine |
| title_fullStr | Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination?
The challenges of a dengue vaccine |
| title_full_unstemmed | Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination?
The challenges of a dengue vaccine |
| title_short | Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination?
The challenges of a dengue vaccine |
| title_sort | which dengue vaccine approach is the most promising and should we be concerned about enhanced disease after vaccination the challenges of a dengue vaccine |
| work_keys_str_mv | AT screatong whichdenguevaccineapproachisthemostpromisingandshouldwebeconcernedaboutenhanceddiseaseaftervaccinationthechallengesofadenguevaccine AT mongkolsapayaj whichdenguevaccineapproachisthemostpromisingandshouldwebeconcernedaboutenhanceddiseaseaftervaccinationthechallengesofadenguevaccine |